Research programme: infectious disease vaccines - NewLink Genetics

Drug Profile

Research programme: infectious disease vaccines - NewLink Genetics

Alternative Names: Alpha-Gal influenza virus vaccines; Influenza virus vaccine - NewLink Genetics; Zika virus vaccine - NewLink Genetics

Latest Information Update: 05 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NewLink Genetics Corporation
  • Class Influenza virus vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza virus infections
  • Research Zika virus infection

Most Recent Events

  • 02 Feb 2016 Early research in Zika virus infection in USA (Parenteral)
  • 27 Aug 2014 Preclinical trials in Influenza virus infections (Prevention) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top